Last updated: February 20, 2026
What is NDC 72205-0136?
NDC 72205-0136 identifies a specific drug product. Based on available data, it corresponds to Vytorin (ezetimibe and simvastatin) tablets, a combination treatment for hyperlipidemia.
Market Size and Trends
Current Market Landscape
- Indication: Hyperlipidemia and cardiovascular risk management.
- Market Players: Vytorin is among several lipid-lowering agents including statins (e.g., atorvastatin, rosuvastatin), PCSK9 inhibitors, and other combination drugs.
- Patient Population: U.S. adults with high cholesterol—approximately 94 million adults have high LDL cholesterol, per CDC [2].
- Market Penetration: Vytorin holds a declining but still significant segment due to generic competition, with sales predominantly driven by patients intolerant to statins alone.
Competitive Environment
- Generic Availability: The patent for Vytorin expired in several jurisdictions, increasing generic competition.
- Alternative Therapies: PCSK9 inhibitors (e.g., evolocumab) have gained favor for high-risk patients.
- Pricing Factors: Patent exclusivity, prescribing habits, and insurance coverage influence market share.
Price Analysis
Current Pricing Data
- Brand-Name Vytorin: Average wholesale price (AWP) approximately $500 for a 30-day supply (30 tablets of 10 mg/10 mg) [3].
- Generic Alternatives: Pricing drops to approximately $20–$40 per 30-day supply.
- Reimbursement: Vytorin's standard co-pay varies but can be upwards of $50–$100 monthly depending on insurance.
Pricing Trends
- Post-Patent Expiration: Prices for Vytorin declined 70–80% upon generic entry.
- Market Dynamics: Insurance formularies favor generics, leading to increased utilization of generics over branded versions.
- Potential Price Changes: As new combination formulations develop and patent states change, prices could stabilize or rise temporarily.
Price Projections
Short-Term (1-2 Years)
- Scenario: Continued generic competition reduces prices further.
- Estimate: Wholesale price for the brand may drop to below $10 per 30-day supply.
- Market Share: Likely to decrease for the brand, with generics dominating over 80% of prescriptions.
Medium to Long-Term (3-5 Years)
- Scenario: Introduction of biosimilar or fixed-dose combination products could stabilize high prices temporarily in niche markets.
- Estimate: Brand prices may rise to $50–$100 if marketed for specific high-risk populations with limited competition.
Factors Influencing Price Movements
- Patent litigation outcomes or extension approvals.
- Adoption of new combination therapies that could replace Vytorin.
- Changes in insurance reimbursement policies.
Regulatory and Market Entry Barriers
- Regulatory Approval: Any new formulations or biosimilars for ezetimibe or simvastatin need FDA approval.
- Market Barriers: Patents protecting Vytorin's combination formulation likely expired or will expire soon, easing generic entries.
- Pricing Regulation: CMS and private insurers influence net prices through formulary decisions.
Summary Table of Price Projections
| Year |
Brand Price (USD) |
Generic Price (USD) |
Key Influences |
| 2023 |
~$500 |
~$20–$40 |
Patent expiration, competition |
| 2024 |
<$50 |
<$10–$20 |
Increased generic market share |
| 2027 |
~$50–$100 |
~$10 |
Niche formulations, market stabilization |
Key Takeaways
- Vytorin (NDC 72205-0136) faces intense generic competition, leading to substantial price reductions.
- The brand price has decreased significantly post-patent expiration, with further declines expected.
- Market share shifts toward generics and alternative therapies reduce the revenue potential for the original branded product.
- Biosimilars and fixed-dose combinations could influence future pricing and market dynamics.
- Reimbursement policies and insurance formularies will continue constraining or expanding access and pricing.
FAQs
1. What is the primary use of NDC 72205-0136?
It is used to lower LDL cholesterol in patients at risk for cardiovascular disease.
2. How does the availability of generics impact the price of Vytorin?
Generic entry causes price declines of up to 80%, reducing profitability for the brand and shifting prescriptions.
3. Are there any regulatory barriers to introducing new formulations of this drug?
Patent expirations generally ease barriers, but new formulations require FDA approval for safety and efficacy.
4. What are the main factors influencing the future price of this drug?
Patent status, competition, insurance reimbursement policies, and the development of new therapies.
5. How does market competition affect sales volumes?
Generics and alternative therapies lead to decreased sales for Vytorin, especially among cost-sensitive prescribers.
References
[1] FDA. (2023). Drug Listing Data. U.S. Food and Drug Administration.
[2] CDC. (2022). High Blood Cholesterol Facts. Centers for Disease Control and Prevention.
[3] Red Book. (2023). Pharmacy Pricing Data. Truven Health Analytics.
